Первичная и вторичная профилактика рака шейки матки (по материалам рекомендаций Американского общества клинической онкологии, март 2017 г.) Часть I

1. De Sanjosé S, Temin S, Garland S et al. Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline Summary. J Oncol Pract 2017; 25: JOP2017021949. DOI: 10.1200/ JOP.2017.021949
2. Forman D, de Martel C, Lacey CJ et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 (Suppl. 5): F12–23. DOI: 10.1016/j.vaccine.2012.07.055
3. Castellsagué X, Alemany L, Quer M et al. HPV involvement in head and neck cancers: Comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst 108:djv403, 2016 HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Nat l Cancer Inst 2016; 108 (6): djv403. DOI: 10.1093/jnci/djv403
4. De Sanjosé S, Serrano B, Castellsagué X et al. Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report. Vaccine 2012; 30 (Suppl. 4): D1–83, vi. DOI: 10.1016/S0264-410X(12)01435-1
5. De Sanjosé S, Wheeler CM, Quint WG et al. Age-specific occurrence of HPV16- and HPV18-related cervical cancer.Cancer Epidemiol Biomarkers Prev 2013; 22 (7): 1313–8. DOI: 10.1158/1055-9965.EPI-13-0053
6. De Sanjosé S1, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11 (11): 1048–56. DOI: 10.1016/S1470-2045(10)70230-8. Epub 2010 Oct 15
7. Wheeler CM, Castellsagué X, Garland SM et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13 (1): 100–10. DOI: 10.1016/ S1470-2045(11)70287-X. Epub 2011 Nov 8
8. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 (Suppl. 5): F123–38. DOI: 10.1016/j.vaccine.2012.04.108
9. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014; 89 (43): 465–91.
10. Couto E, Sæterdal I, Juvet LK, Klemp M. HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health 2014; 14: 867. DOI: 10.1186/1471-2458-14-867
11. Public Health Agency of Canada National Advisory Committee on Immunization: Update on the recommendedhu man papillomavirus (HPV) vaccine immunization schedule. https://www.canada.ca/en/public-health/services/publications/healthy-living/update recommended-human-papillomavirus-vaccine-immunization-schedule.html
12. Vichnin M, Bonanni P, Klein NP et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J 2015; 34 (9): 983–91. DOI: 10.1097/INF.0000000000000793
13. Garland SM, Ault KA, Gall SA et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009; 114 (6): 1179–88. DOI: 10.1097/AOG. 0b013e3181c2ca21
14. Brotherton JM. Safety of the quadrivalent human papillomavirus vaccine. BMJ 2013; 347: f5631. DOI: 10.1136/bmj.f5631
15. Arnheim-Dahlström L, Pasternak B, Svanström H et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347: f5906. DOI: 10.1136/bmj.f5906
16. Global Advisory Committee on Vaccine Safety, 2–3 December 2015. Wkly Epidemiol Rec 2016; 91 (3): 21–31.
17. Markowitz LE, Dunne EF, Saraiya M et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56 (RR-2): 1–24.
18. Chuang LT, Temin S, Berek JS. Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. J Oncol Pract 2016; 12 (7): 693–6. DOI: 10.1200/JOP.2016.014290. Epub 2016 Jun 21
19. Jeronimo J, Castle PE, Temin S, Shastri SS. Secondary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. J Oncol Pract 2017; 13 (2): 129–33. DOI: 10.1200/JOP.2016.017889. Epub 2016 Nov 15
20. Massad LS, Einstein MH, Huh WK et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013; 121 (4): 829–46. DOI: 10.1097/AOG.0b013e3182883a34
21. World Health Organization: WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention: WHO Guidelines Approved by the Guidelines Review Committee. Geneva, Switzerland, World Health Organization, 2013.
22. Arnheim-Dahlström L, Pasternak B, Svanström H et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347: f5906. DOI: 10.1136/bmj.f5906.
23. Markowitz LE, Dunne EF, Saraiya M et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63 (RR–05): 1–30.
24. European Medicines Agency: HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS http://www.ema.europa.eu/ema/index. jspcurl5 pages/ medicines/ human/referrals/Human_papillomavirus _vaccines/ human_referral_prac_ 000053. jsp&mid5 WC0b01ac05805c516f
25. Centers for Disease Control and Prevention, Food and Drug Administration: Vaccine Adverse Event Reporting System (VAERS). https://vaers.hhs.gov/index
26. Garland SM, Stanley M, Brotherton J et al. IPVS policy statement on safety of HPV vaccines. Papillomavirus Res 2: 9–10, 2016.
27. Meites E, Kempe A, Markowitz LE. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination-Updated Recommendations of the Advisory Committee on Immunization Practices. Am J Transplant 2017; 17 (3): 834–7. DOI: 10.1111/ajt.14206
28. Garland SM, Subasinghe AK, Jayasinghe YL et al. HPV vaccination for victims of childhood sexual abuse. Lancet 2015; 386 (10007): 1919–20. DOI: 10.1016/S0140-6736(15)00757-6. Epub 2015 Nov 13
29. Bailey HH, Chuang LT, du Pont NC et al. American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. J Clin Oncol 2016; 34 (15): 1803–12. DOI: 10.1200/JCO.2016. 67.2014. Epub 2016 Apr 11.

Светлана Олеговна Дубровина – 
д-р мед. наук, проф., проф. каф. акушерства 
и гинекологии №1 ФГБОУ ВО РостГМУ 
Минздрава России, гл. науч. сотр. 
ФГБУ РНИИАП.